MedTrace Logo

Pazopanib for Metastatic Alveolar Soft Part Sarcoma

NCT02113826 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-11-06

No results posted yet for this study

Summary

Alveolar soft part sarcoma (ASPS), a rare subset of STS (\<1%) harbors t(X;17)(p11;q25) translocation and produces resultant ASPL-TFE3 fusion protein. Due to its nature of high expression of angiogenic factors, sunitinib and cediranib produced overall response rates of 55% and 43%, respectively. However, the efficacy of pazopanib is unknown in metastatic ASPS.

Conditions

  • Metastatic Alveolar Soft Part Sarcoma

Interventions

DRUG

Pazopanib

Pazopanib 800mg qd daily for 4 weeks = 1 cycle

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Asan Medical Center

    collaborator OTHER

  • Samsung Medical Center

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-09-30
Completion
2017-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02113826 on ClinicalTrials.gov